MedTrace Logo

Adoptive Transfer of pp65-specific T Cells for the Treatment of Refractory Cytomegalovirus (CMV) Infection

NCT02346617 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2020-03-20

No results posted yet for this study

Summary

To evaluate the safety and efficacy for treatment of persistent CMV infection in hematopoietic cell transplant (HCT) recipients.

Conditions

  • Cytomegalovirus Infections

Interventions

BIOLOGICAL

IFN-γ positive selected T-cells

No intervention

Sponsors & Collaborators

  • Miltenyi Biotec B.V. & Co. KG

    collaborator INDUSTRY

  • Yae-Jean Kim

    lead OTHER

Principal Investigators

  • Yae-Jean Kim, MD, PhD · Samsung Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2023-12-01
Completion
2024-12-01

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02346617 on ClinicalTrials.gov